Keros to Start Rinvatercept DMD Trial in Q1 2026, Plans ALS Regulatory Talks
Keros Therapeutics plans a phase II DMD trial of rinvatercept in Q1 2026 and regulatory talks for ALS in H2 2026. Cash stands at $383 million with runway into H1 2028.
Pulmonary Arterial Hypertension
DiseaseDisease Profile
Pulmonary arterial hypertension is a progressive pulmonary vascular disease characterized by elevated pulmonary arterial pressure and vascular remodeling, which can lead to right ventricular failure.
- Category
- pulmonary vascular disease
- Prevalence
- Estimated prevalence is approximately 15 to 50 cases per million adults.
Related News
Merck Strengthens Oncology Pipeline as Keytruda Faces 2028 Patent Expiry
Merck & Co. is bolstering its oncology pipeline with acquisitions like Terns Pharmaceuticals and Cidara Therapeutics, while Keytruda remains the key growth driver. It expects Keytruda peak sales of $35 billion by 2028 and aims to launch 20 new drugs by 2030.
Insmed Reports Q2 2026 Revenues of $425.5M, Raises BRINSUPRI Guidance and Peak Sales Estimates
Insmed reported Q2 2026 revenues of $425.5M, with BRINSUPRI at $309.2M. It raised 2026 BRINSUPRI guidance to $1.25B-$1.40B and lifted peak revenue estimates for its lead programs to over $14B.
Merck reports Phase 2 CADENCE data for WINREVAIR in CpcPH-HFpEF
Merck reported Phase 2 CADENCE results showing WINREVAIR met the primary endpoint in adults with CpcPH-HFpEF. The company said the data support advancement into a registrational Phase 3 study.
Biotech Investors Eye Cystic Fibrosis Trials and Rare-Disease Drugs
Biotech investors are closely watching cystic fibrosis drug trials, rare-disease therapies and regulatory catalysts. Sionna Therapeutics is advancing a new CF drug class, while Praxis Precision Medicines targets essential tremor. FDA staffing challenges add uncertainty to approval timelines.
Seralutinib Shows Mixed Results in Phase 3 PAH Trial, Winrevair Benefits Heart Failure-Related PH
Phase 3 trial results show seralutinib missed its primary endpoint in PAH but showed benefit in advanced disease subgroups. Meanwhile, Winrevair demonstrated significant reductions in pulmonary vascular resistance in heart failure-related pulmonary hypertension in a Phase 2 study.
Merck Acquires Terns Pharmaceuticals for $6.7 Billion to Bolster Cancer Pipeline
Merck will acquire Terns Pharmaceuticals for $6.7 billion to bolster its cancer pipeline ahead of Keytruda's 2028 patent expiration. The deal gives Merck access to TERN-701, an oral tyrosine kinase inhibitor for chronic myeloid leukemia. Merck projects over $70 billion in commercial opportunities from its pipeline by the mid-2030s.
Orphan Drug Market Projected to Reach $409 Billion by 2032, Driven by Rare Disease Treatments
Global orphan drug sales are forecast to reach $409 billion by 2032, representing one-fifth of prescription drug sales, with Johnson & Johnson and Argenx leading the market amid regulatory uncertainty.
Healthcare Sector Leads S&P 500 as Pharma Giants Navigate 2026 Market Shift
Healthcare sector surged 10% since Q4 2025, outpacing all S&P 500 sectors as investors rotate from tech to pharmaceutical value plays. Major drugmakers demonstrate resilience following Medicare price negotiations implementation.
Insmed Reports Strong 2025 Results, FDA Grants Orphan Drug Status to Treprostinil Palmitil
Insmed reported total revenues of $606.4 million for 2025, with ARIKAYCE growing 19% annually. The FDA granted orphan drug designation to treprostinil palmitil for pulmonary arterial hypertension treatment in January 2026.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07761572 |
CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension |
NOT_YET_RECRUITING | PHASE2 |
| NCT07751120 |
Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in PAH. |
NOT_YET_RECRUITING | PHASE1 |
| NCT07737522 |
Myocardial Metabolic Flux in Pulmonary Arterial Hypertension |
NOT_YET_RECRUITING | PHASE2 |
| NCT07717060 |
Extracellular Vesicle Dynamics Predicting Vascular Complications and Treatment Response in Systemic Sclerosis |
NOT_YET_RECRUITING | NA |
| NCT07700303 |
Withdrawal of Prostacyclin Pathway Therapy in Patients With Pulmonary Arterial Hypertension Receiving Sotatercept (WATERLOO) |
NOT_YET_RECRUITING | NA |
| NCT07667673 |
Multimodality RV Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 PAH |
RECRUITING | |
| NCT07646860 |
A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032) |
RECRUITING | PHASE2 |
| NCT07623525 |
DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia |
RECRUITING | PHASE1/PHASE2 |
| NCT07613099 |
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging |
RECRUITING | PHASE3 |
| NCT07612657 |
A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations |
NOT_YET_RECRUITING | PHASE3 |